CT26-hCD24
Strain Information
Validation Data
Figure 1. Expression of human CD24 on CT26-hCD24 cells was confirmed by flow cytometry.
CT26-hCD24 cells and wild type CT26 cells were stained with species-specific anti- CD24 antibodies. FACS analysis shows that human CD24 but not mouse CD24 was exclusively detectable on CT26-hCD24 cells.
Figure 2. In vivo tumor growth curves in humanized CT26-hCD24 syngeneic model.
BALB/c mice were subcutaneously injected 1×106 CT26-hCD24 cells compared with wild type CT26 cells as control. Tumor growth was monitored by measuring tumor size from day 5 after subcutaneous implantation.
Data shows that there were no significant differences between CT26-hCD24 cells and wild type CT26 cells in either tumorigenicity or tumor growth.
Figure 3. FACS analysis of CD24 expression on tumor cells derived from humanized CT26-hCD24 syngeneic model with species-specific anti-CD24 antibodies.
Data shows that human CD24 knock-in tumor exclusively express human CD24 but not mouse CD24.
Related Strain(s)
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
